GNI to develop EpiCept's hepatitis drug in Asia
This article was originally published in Scrip
Executive Summary
The US biotech company EpiCept has licensed its pipeline compound EP1013 to the Japanese bioventure GNI for development for hepatitis-related hepatic disorders in Asia, Australia and New Zealand.